Science

James Davis: Ide-cel vs cilita-cel in R/R multiple myeloma

James Davis/X

Feb 23, 2025, 10:27

James Davis: Ide-cel vs cilita-cel in R/R multiple myeloma

James Davis, Assistant professor & malignant hematology pharmacist at MUSC Hollings Cancer Center, shared an article by Doris K. Hansen, et al. on X:

“In lieu of a head-to-head trial comparing ide-cel and cilta-cel (which we will never get), check out our study in Journal of Clinical Oncology comparing these products in over 600 patients.

Congrats Doris Hansen, Krina Patel, Surbhi Sidana, Danai Dima, Charlotte B Wagner.”

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.

Authors: Doris K. Hansen, et al.

James Davis: Ide-cel vs cilita-cel in R/R multiple myeloma

cancer CharlotteBWagner Ciltacabtagene Autoleucel Danai Dima Doris Hansen Doris K. Hansen fight against cancer Global fight against cancer idecabtagene vicleucel James Davis Journal of Clinical Oncology Krina Patel multiple myeloma MUSC Hollings Cancer Center OncoDaily Oncology Surbhi Sidana

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth